{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T05:29:55Z","timestamp":1782019795221,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.clml.2020.10.014","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T07:44:52Z","timestamp":1604043892000},"page":"e477-e482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Invasive Mold Infections in FLT3-Mutated Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-4830","authenticated-orcid":false,"given":"Pakpoom","family":"Phoompoung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Daher-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Sibai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.10.014_bib1","first-page":"3221","article-title":"European guidelines for primary antifungal prophylaxis in adult hematology patients: summary of the updated recommendations from the European Conference on Infections in Leukemia","volume":"73","author":"Maertens","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.clml.2020.10.014_bib2","doi-asserted-by":"crossref","first-page":"e0128410","DOI":"10.1371\/journal.pone.0128410","article-title":"High incidences of invasive fungal infections in acute myeloid leukemia patients receiving induction chemotherapy without systemic antifungal prophylaxis: a prospective observational study in Taiwan","volume":"10","author":"Tang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2020.10.014_bib3","first-page":"e1097851","article-title":"Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: a retrospectice cohort study","volume":"13","author":"Lein","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2020.10.014_bib4","first-page":"3613","article-title":"High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes","volume":"27","author":"Nganthavee","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2020.10.014_bib5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/myc.12646","article-title":"Invasive fungal infection following chemotherapy for acute myeloid leukemia\u2014experience from a developing country","volume":"60","author":"Korula","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.clml.2020.10.014_bib6","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.21776","article-title":"Invasive fungal disease in patients treated for newly diagnosed acute leukemia","volume":"85","author":"Hammond","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.10.014_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.diagmicrobio.2012.10.001","article-title":"Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy","volume":"75","author":"Neofytos","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clml.2020.10.014_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornerly","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.10.014_bib9","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-019-03744-5","article-title":"Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis","author":"Rodriguez-Veiga","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.10.014_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.23388","article-title":"The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole","volume":"88","author":"Barreto","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.10.014_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040620719827310","article-title":"Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia","volume":"10","author":"Short","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2020.10.014_bib12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge","volume":"32","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.10.014_bib13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.10.014_bib14","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.10.014_bib15","first-page":"629381","article-title":"Management of midostaurin-CYP3A4 drug\u2013drug interactions in patients with acute myeloid leukemia","volume":"33","author":"Schlafer","year":"2019","journal-title":"Oncology"},{"key":"10.1016\/j.clml.2020.10.014_bib16","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/QCO.0000000000000611","article-title":"Azole antifungals and new targeted therapies for hematological malignancy","volume":"32","author":"Lindsay","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.clml.2020.10.014_bib17","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1038\/bcj.2015.61","article-title":"Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length","volume":"5","author":"Kim","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2020.10.014_bib18","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","author":"Donnelly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2020.10.014_bib19","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"Cheson","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.10.014_bib20","doi-asserted-by":"crossref","first-page":"ofz176","DOI":"10.1093\/ofid\/ofz176","article-title":"Incidence and risk factors for breakthrough invasive mold infections in acute myeloid leukemia patients receiving remission induction chemotherapy","volume":"6","author":"Patel","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.clml.2020.10.014_bib21","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"Le r\u00f4le de FLT3 dans les tumeurs malignes h\u00e9matopo\u00ef\u00e9tiques","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2020.10.014_bib22","doi-asserted-by":"crossref","first-page":"9759","DOI":"10.1073\/pnas.1005186107","article-title":"FLT3 permits survival during infection by rendering dendritic cells competent to activate NK cells","volume":"107","author":"Eidenschenk","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2020.10.014_bib23","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1164\/rccm.200608-1068OC","article-title":"Lung dendritic cells elicited by Fms-like tyrosine 3-kinase ligand amplify the lung inflammatory response to lipopolysaccharide","volume":"176","author":"Von Wulffen","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clml.2020.10.014_bib24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1084\/jem.20021900","article-title":"Flt3 ligand-treated neonatal mice have increased innate immunity against intracellular pathogens and efficiently control virus infections","volume":"197","author":"Vollstedt","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2020.10.014_bib25","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.4049\/jimmunol.1500690","article-title":"Wagage SFlt3 ligand is essential for survival and protective immune responses during toxoplasmosis","volume":"195","author":"Dupont","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2020.10.014_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bcmd.2007.06.016","article-title":"Provision of antifungal immunity and concomitant alloantigen tolerization by conditioned dendritic cells in experimental hematopoietic transplantation","volume":"40","author":"Montagnoli","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.clml.2020.10.014_bib27","doi-asserted-by":"crossref","first-page":"e89560","DOI":"10.1371\/journal.pone.0089560","article-title":"Activating FLT3 mutations show distinct gain-of-function phenotypes in\u00a0vitro and a characteristic signalling pathway profile associated with prognosis in acute myeloid leukemia","volume":"9","author":"Janke","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2020.10.014_bib28","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.3324\/haematol.2014.104331","article-title":"Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function","volume":"99","author":"Wolleschak","year":"2014","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020305814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020305814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:38Z","timestamp":1761870938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020305814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S2152265020305814"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.10.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Invasive Mold Infections in FLT3-Mutated Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}